Invivyd Inc. has released positive initial results from its ongoing Phase 1 clinical trial of VYD222, a monoclonal antibody candidate designed to prevent symptomatic COVID-19 in immunocompromised people. The drug has been well-tolerated at all dose levels, with no serious adverse events reported so far. Early serum samples from the first, lowest dose cohort showed strong neutralization activity against Omicron XBB.1.5, one of the dominant SARS-CoV-2 variants circulating globally.
The company plans to use these analyses and published clinical outcome data from prior clinical trials to guide VYD222 dose selection for its pivotal clinical trial.
VYD222 is a broadly neutralizing monoclonal antibody candidate intended for preventing symptomatic COVID-19 in vulnerable populations such as immunocompromised individuals who may not respond adequately to COVID-19 vaccination.
Monoclonal antibodies directed against the receptor binding domain of the SARS-CoV-2 spike protein provide an attractive safety profile, even at higher doses.